This open-label trial tested the safety, tolerability and efficacy of an acute dose of CT38s (a short-lived, CRFR2-selective agonist, with no known off-target activity) in 14 ME/CFS patients. The gene discussed is CRHR2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.